Jason Rhodes, President, CFO and Treasurer at Epizyme, holds 847.32K shares in Dyne Therapeutics (Ticker: DYN), holds 8.28M shares in Generation Bio (Ticker: GBIO), holds 3.23M shares in Replimune Group (Ticker: REPL). Most recently, Jason Rhodes Sold ― shares of Dyne Therapeutics on Nov 18, 2024 for an estimated value of 25.88K.
What is the percentage of profitable transactions made by Jason Rhodes?
The percentage of profitable transactions made by Jason Rhodes is 33%.
What is the average return per transaction made by Jason Rhodes?
The average return per transaction made by Jason Rhodes is 78.70%.
What stocks does Jason Rhodes hold?
Jason Rhodes holds: EPZM, REPL, GBIO, DYN, IRON stocks.
What was Jason Rhodes’s latest transaction?
Jason Rhodes latest transaction was an Informative Sell of $25.88K.
What was Jason Rhodes's most profitable transaction?
Jason Rhodes’s most profitable transaction was an Informative Buy of REPL stock on November 20, 2019. The return on the trade was 276.70%.
What is Jason Rhodes's role in Epizyme?
Jason Rhodes's role in Epizyme is President, CFO and Treasurer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.